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Abstract: Cationic polymers are promising components of the versatile platform of non-viral nucleic
acid (NA) delivery agents. For a successful gene delivery system, these NA vehicles need to comprise
several functionalities. This work focuses on the modification of oligoaminoamide carriers with
hydrophilic oligomer blocks mediating nanoparticle shielding potential, which is necessary to
prevent aggregation or dissociation of NA polyplexes in vitro, and hinder opsonization with blood
components in vivo. Herein, the shielding agent polyethylene glycol (PEG) in three defined lengths
(12, 24, or 48 oxyethylene repeats) is compared with two peptidic shielding blocks composed of
four or eight repeats of sequential proline-alanine-serine (PAS). With both types of shielding agents,
we found opposing effects of the length of hydrophilic segments on shielding and compaction of
formed plasmid DNA (pDNA) nanoparticles. Two-arm oligoaminoamides with 37 cationizable
nitrogens linked to 12 oxyethylene units or four PAS repeats resulted in very compact 40–50 nm
pDNA nanoparticles, whereas longer shielding molecules destabilize the investigated polyplexes.
Thus, the balance between sufficiently shielded but still compact and stable particles can be considered
a critical optimization parameter for non-viral nucleic acid vehicles based on hydrophilic-cationic
block oligomers.
Keywords: complex stability; nanoparticle; oligoamine; nucleic acid delivery; plasmid DNA (pDNA);
polyethylene glycol (PEG); polyplex; shielding
1. Introduction
In modern cancer therapy, conventional chemotherapy and surgery often fail [1]. Nevertheless,
with the field of gene therapy, a novel opportunity has reached clinical application [2–4]. Despite
all the benefits of viral gene therapy, it also comes with certain disadvantages, such as limited
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re-administration due to immediate inflammatory or delayed humoral or cellular immune response.
In the last decades, much focus has also been put on non-viral gene therapy [5,6]. Polymeric
vehicles such as linear polyethylenimine (lPEI) with its repetitive diaminoethane motif can address
different stages of the delivery pathway in a way similar to viruses [6–8]. Polycations can stably
bind and compact pDNA into “polyplexes” [9] with virus-like nanodimensions [10]. Size, stability,
and shape of nanoparticles [11,12] play a crucial role for the in vivo biodistribution and survival of
nanoparticles, as well as cellular uptake processes [13]. Following cellular uptake by endocytosis,
endolysosomal escape of nanoparticles presents a significant bottleneck in the transfection process.
lPEI polyplexes are quite effective at this stage due to the endosomal buffering (“proton sponge”)
diaminoethane motif [14–19]. Nevertheless, the toxicity [20,21] and polydispersity [22] of lPEI led us to
the development of diaminoethane motif-containing building blocks suitable for solid phase synthesis
(SPS) [23,24]. With the help of SPS, it is possible to synthesize multifunctionalized defined oligomers
for gene delivery [25–30].
The introduction of a shielding domain into artificial gene carriers is crucial in the first phase
of the delivery process to reduce unwanted interaction between blood and pDNA polyplexes.
Polyethylene glycol (PEG) represents the most prominent and well-established shielding agent [31,32],
and has been used for shielding cationic polyplexes in numerous instances [33–38]. It was recently
found that PEGylation may cause an immunogenic response [39–44]; thus, several alternatives have
also been evaluated for this polyplex shielding, such as poly(N-(2-hydroxypropyl)methacrylamide)
(pHPMA) [45–47], hydroxyethyl starch (HES) [48], polysarcosine (pSar) [49,50], oligosaccharides [46,51],
or proteins [52]. Recently, recombinant PAS composed of repeats of the natural amino acid sequence
proline-alanine-serine was reported as an alternative to PEG [53,54].
Aside from having clearly positive effects such as improved blood circulation times and increased
tumor accumulation, polyplex shielding may also provide negative drawbacks, such as a reduced
intracellular performance and/or reduced plasmid DNA (pDNA) compaction; this dilemma can be at
least partly overcome by programmed deshielding [38,55,56]. The current paper focuses on the relation
of polyplex shielding with pDNA compaction, size, shape, and stability. For this purpose, we compare
oligoaminoamide co-oligomers with different PEG lengths or defined numbers of PAS repeats which
were generated by SPS. We focused on the effect of the shielding block attached in T-shape topology
onto a “two-arm” structure of oligoaminoamide oligomers tailored for pDNA delivery. The oligomer
library for this study consisted of oligomers decorated with four or eight repetitions of PAS as well as
PEG of 12, 24, or 48 ethylene oxide (EO) units in length, or a three-arm oligomer without shielding,
respectively. Oligomers were compared and evaluated in different physicochemical and biological
assays to elucidate the impact of shielding agent on critical polyplex characteristics.
2. Materials and Methods
2.1. Materials
2-Chlorotrityl chloride resin was purchased from Iris Biotech (Marktredwitz, Germany),
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-hexafluorophosphate (HBTU), syringe reactors
(PP reactor with PE frit) from Multisyntech GmbH (Witten, Germany). All amino acids, peptide
grade dimethylformamide (DMF), N,N-diisopropylethylamine (DIPEA), and trifluoroacetic acid
(TFA) were purchased from Iris Biotech (Marktredwitz, Germany). The cationic building block
Fmoc-Stp(Boc)3-OH (Stp: succinyl-tetraethylene pentamine; Boc: tert-butyloxycarbonyl) was prepared
as described in [57]. 1-Hydroxy-benzotriazole (HOBt), triisopropylsilane (TIS), dimethylsulfoxide
(DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and Triton X-100 were
obtained from Sigma-Aldrich (Munich, Germany). N-hexane and tert-butyl methyl ether (MTBE)
were obtained from Brenntag (Mühlheim an der Ruhr, Germany). Dichloromethane was obtained
from Bernd Kraft (Duisburg, Germany). Fmoc-N-amido-dPEG12/24-acid® was purchased from Quanta
Biodesign (Powell, OH, USA). 1,2-Ethanedithiol (EDT) was purchased from Sigma-Aldrich (Munich,
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Germany). All solvents and other reagents were acquired from Sigma-Aldrich (Munich, Germany), Iris
Biotech (Marktredwitz, Germany), Merck (Darmstadt, Germany), or AppliChem (Darmstadt, Germany).
All cell culture consumables were obtained from NUNC (Langenselbold, Germany), TPP
(Trasadingen, Switzerland), or Sarstedt (Nümbrecht, Germany). DMEM medium was purchased
from Sigma Aldrich (Munich, Germany). RPMI medium, fetal bovine serum (FBS), cell culture media,
and antibiotics were purchased from Invitrogen (Karlsruhe, Germany), glucose from Merck (Darmstadt,
Germany), HEPES from Biomol GmbH (Hamburg, Germany), and sodium chloride from Prolabo
(Haasrode, Belgium). Agarose NEEO Ultra-Qualität was obtained from Carl Roth GmbH (Karlsruhe,
Germany) and GelRed™ from VWR (Darmstadt, Germany). Heparin sulfate was purchased from
Ratiopharm (Ulm, Germany) with 5000 IU/mL. Luciferase cell culture 5× lysis buffer and D-luciferin
sodium were obtained from Promega (Mannheim, Germany).
2.2. Oligomer Synthesis
Peptide synthesis was carried out using Fmoc-chemistry and L-amino acids. Prior to synthesis,
2-chlorotrityl chloride resins were loaded with the appropriate C-terminal amino acids. Coupling was
carried out with 4 eq. of HBTU, 4 eq. of DIPEA, 4 eq. of HOBt, and 4 eq. of Fmoc-protected amino
acid per free amine on the solid support; the solution was supplemented with 1% Triton X-100 (v/v).
Amino acids and HOBt were dissolved in NMP (N-methylpyrrolidone), supplemented with Triton-X.
HBTU was dissolved in DMF, and DIPEA diluted with NMP. Peptide synthesis was carried out using
an automated Syro Wave (Biotage, Uppsala, Sweden) with a microwave cavity. Double couplings were
performed at 50 ◦C for 12 min prior to five repetitive washing steps. Fmoc removal was conducted by
standard deprotection methods with 40% piperidine in DMF (v/v) supplemented with 1% Triton-X
for 5 × 10 min.
Resins for two-armed oligomers were loaded with Dde-L-Lys(Fmoc)-OH, and for three-arm
oligomers with Fmoc-L-Cys(Trt)-OH, as described in the Supplementary Materials. After loading
determination and Fmoc removal, Fmoc-Ser(tBu)-OH, Fmoc-Ala-OH, and Fmoc-Pro-OH (from now
on called PAS) were attached sequentially, with four or eight triple sequence repeats (PAS4, PAS8) in
the case of PAS-shielded oligomers, while PEG controls were synthesized by attachment of precise
bifunctional Fmoc-N-amido-dPEG12-OH or Fmoc-N-amido-dPEG24-OH. At this step, an analytical
cleavage of a small fraction was done and MALDI-TOF mass spectrometry of the Dde-K-(PAS)8 peptide
was carried out (see Figure S6).
Next, the cationic backbone of the oligomers was built, based on alternating Stp and histidine units,
a lysine branching point, and terminal cysteines for cross-linkage. Therefore, Fmoc-L-His(Trt)-OH,
Fmoc-L-Lys(Fmoc)-OH, our cationic building block Fmoc-Stp(Boc)3-OH [23], and Boc-L-Cys(Trt)-OH
were coupled following the sequence in Table 1. A detailed step-by-step description of the synthesis of
Fmoc-Stp(Boc)3-OH, of the cationic backbone, and of the three-arm oligomer can be found in [57]. In the
case of shielded oligomers, the resins loaded with Dde-L-Lys-PAS4/PAS8/dPEG12/dPEG24/dPEG48
were placed separately into the microwave cavity of the Syro Wave (Biotage, Uppsala, Sweden) peptide
synthesizer, and synthesis was conducted under the conditions described above until the last coupling
of N-terminal cysteine.
In the case of non-shielded three-arm oligomer, a Cys(Trt)-OH preloaded 2-chlorotrityl resin was
used and automated microwave-assisted synthesis was carried out to obtain the sequence mentioned
in Table 1. All oligomers were ended by a double coupling of Boc-Cys(Trt)-OH for 2 × 1 h at room
temperature to avoid racemization.
Synthesis of cMet-targeted oligomers (containing a cMet-binding peptide, cmb) can be found in
the experimental section of Supplementary Materials.
After the final coupling step, the resins were dried and the products cleaved off the resin for
90 min using a mixture of TFA/EDT/H2O/TIS 94:2.5:2.5:1 (v/v) at a ratio of 10 mL per gram resin.
The cleaved oligomers were purified by size exclusion chromatography (SEC) performed with
10 mM hydrochloric acid/acetonitrile 7:3 as solvent. An ÄKTA purifier system (GE Healthcare
Polymers 2017, 9, 142 4 of 20
Biosciences, Uppsala, Sweden) equipped with a Sephadex G-10 column and a P-900 solvent pump module,
a UV-900 spectrophotometrical detector, a pH/C-900 conductivity module, and a Frac-950 automated
fractionator was used. The product fractions were collected and combined prior to lyophilisation.
Analytical data of 1H-NMR and reversed phase high-performance liquid chromatography
(RP-HPLC) can be found in Figures S7–S30.
2.3. Polyplex Formation
Indicated amounts of pCMVLuc (CMV: cytomegalovirus promotor; Luc: firefly luciferase gene)
and oligomer at indicated nitrogen/phosphate (N/P) ratios were diluted in separate tubes. If not
otherwise mentioned, suspension media was 20 mM HEPES buffered 5% glucose at pH 7.4 (HBG 7.4).
Diluted oligomer and diluted pDNA were always mixed at similar volume.
For N/P ratio calculation, only the protonatable amino groups of the Stp units and N-terminal
amines of cysteine residues were considered (N number) and related to the anionic phosphate groups
(P number) in pDNA. Note that protonatable amines outside of the cationic backbone and protonatable
imidazole nitrogens of histidines were not taken into account for calculation of N (for reasons of
consistency with our previous work). The nucleic acid was added to the oligomer, mixed vigorously,
and incubated for 30 min at room temperature under air exposure to enhance disulfide formation.
2.4. Polyplex Stability in the Presence of Salt
Polyplexes were prepared with oligomers at N/P 12 and 2 µg pCMVLuc in a total volume of
60 µL deionized water. After 30 min, 500 µL of phosphate-buffered saline (PBS) was added and a
dynamic laser-light scattering (DLS) measurement with three runs (including six sub-runs each) was
performed immediately. Samples were incubated at room temperature, and further measurements
after 5, 30, 60, and 180 min were conducted.
2.5. Erythrocyte Adhesion in the Presence or Absence of Serum
Polyplexes were prepared at N/P 12 and 2 µg pDNA (20% Cy5 labeled) in a total volume of 60 µL
HBG. After 30 min, three groups were treated differently. Either HBG, 3 × 106 erythrocytes in HBG,
or serum (to a final concentration of 90%) were added. After further 30 min of incubation at 37 ◦C,
erythrocytes containing polyplexes were sedimented by centrifugation (1500 rpm for 10 min at room
temperature) and the supernatant was taken. Then, 3500 IU of heparin sulfate was added to dissociate
the polyplex and determine the remaining amount of pDNA via Cy5 excitation/emission (λex = 649 nm
and emission wavelength λem = 670 nm). Data were calculated in comparison to equally treated free
pDNA. Self-quenching and efficacy of release with 3500 IU heparin can be found in Figure S1.
2.6. Particle Size and Zeta Potential
Particle size and zeta potential of polyplexes were measured by dynamic laser-light scattering
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) and transmission electron
microscopy (TEM) with a JEM 1011 (Jeol, Freising, Germany).
For DLS measurements, 2 µg pDNA was dissolved in 30 µL HBG and was added to an amount of
oligomers corresponding to N/P 12 in 30 µL HBG. After 30 min of incubation at room temperature,
740 µL of 10 mM sodium chloride solution (pH 7.4) was added and the samples were measured.
Results were plotted as Z-Average and SD out of three runs with 12 sub-runs each. Zeta potential (ZP)
is displayed as average (mV) of three runs with up to 15 sub-runs each.
For TEM, samples were prepared as follows. The formvar/carbon-coated 300 mesh copper grids
(Ted Pella Inc., Redding, CA, USA) were activated by mild plasma cleaning. Afterwards, the grids
were incubated with 20 µL of the polyplex solution at N/P 12 for 2.5 min previously prepared in
water. Excess liquid was blotted off using filter paper until the grid was almost dry. Prior to staining,
the grids were washed with 5 µL of staining solution for 5 s. Then, the copper grids were incubated
with 5 µL of a 2% aqueous uranylformate solution for 20 s, excess liquid was blotted off using filter
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paper, followed by air-drying for 30 min. Samples were then analyzed using a JEM 1011 (Jeol, Freising,
Germany) operated at 80 kV.
2.7. Ethidium Bromide Compaction Assay and Heparin Stress
Polyplexes containing 2 µg pDNA were formed at N/P ratios of 6 and 12 in a total volume of
200 µL HBG. lPEI polyplexes formed at N/Ps 6 and 12 served as a positive control. HBG buffer (200 µL)
served as blank, and 2 µg pDNA in 200 µL HBG buffer was considered as maximum ethidium bromide
(EtBr) fluorescence intensity (100% value). These samples were prepared in parallel to the polyplexes.
After 30 min of incubation at room temperature, 700 µL of EtBr solution (c = 0.5 µg/mL) were added.
The fluorescence intensity of EtBr was measured after an additional 3 min incubation using a Cary
Eclipse spectrophotometer (Varian, Germany) at the excitation wavelength λex = 510 nm and emission
wavelength λem = 590 nm. The fluorescence intensity of EtBr was determined in relation to the 100%
value. As a further experiment, 250 IU of heparin (Ratiopharm, Ulm, Germany) was added to the
samples after EtBr addition to investigate polyplex stability against polyanionic stress.
2.8. Serum Stability of Polyplexes
Determination of polyplex stability against 90% FBS was determined by DLS. Polyplexes were
prepared as described previously with 8 µg pDNA and oligomers at N/P 12 in a total volume of
50 µL HBG. After incubation for 30 min, 30 µL of HBG and 720 µL FBS were added to reach a final
concentration of 90% FBS. Sixty microliters were placed in a DTS1070 cuvette, and t = 0 min was
determined. Then, polyplexes in serum were incubated under steady shaking at 37 ◦C and aliquots
were taken for further measurements after 30, 120, 240 min, and 24 h. Each time point represents one
measurement averaged from 15 sub runs.
2.9. Cell Culture
A mouse neuroblastoma cell line (Neuro-2a) as well as the human hepatocellular carcinoma
cell line Huh7 were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (1 g/L glucose),
while human prostate cancer cell line (DU145) was cultured in RPMI-1640 medium. All media
were supplemented with 10% fetal bovine serum, 4 mM stable glutamine, 100 U/mL penicillin,
and 100 µg/mL streptomycin. Cell lines were cultured at 37 ◦C and 5% CO2 in an incubator with a
relative humidity of 95%.
2.10. In Vitro Gene Transfer
Cells were seeded 24 h prior to pDNA delivery in 96-well plates. For transfections of Neuro-2a
and DU145, 10,000 cells/well were seeded, and 8000 cells/well were seeded in the case of Huh7.
Transfection efficiency of oligomers was evaluated using 200 ng pCMVLuc per well. Polyplexes were
formed at different N/P ratios in a total volume of 20 µL HBG. Before treatment, the cell culture
medium was exchanged with 80 µL fresh medium containing 10% FBS. Polyplex solution was added
to each well and incubated on cells at 37 ◦C for a determined period of time (45 min or 24 h). In the
first case, medium was replaced 45 min after transfection by fresh medium. For control experiments,
only fresh medium was added. In the second case, cells were incubated with polyplex solution for
24 h after initial transfection. All experiments were performed in quintuplicate. lPEI (N/P 6) was used
as a positive control, and HBG buffer was used as a negative control.
For the luciferase assay, 24 h after initial transfection, medium was removed and cells were treated
with 100 µL luciferase cell culture 5× lysis buffer. Luciferase activity in the cell lysate was measured
by using a Centro LB 960 plate reader luminometer (Berthold Technologies, Bad Wildbad, Germany)
and LAR buffer supplemented with 1 mM luciferin. Transfection efficiency was evaluated as relative
light units (RLU) per well.
For the metabolic activity of transfected cells, 24 h after initial transfection, 10 µL of MTT was
added to each well, reaching a final concentration of 0.5 mg/mL. Medium with unreacted dye was
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removed after an incubation time of 2 h at 37 ◦C. The 96-well plates were stored at −80 ◦C for at
least one hour, and afterwards the purple formazan product was dissolved in 100 µL DMSO per
well. The absorbance was determined by using a microplate reader (TecanSpectrafluor Plus, Tecan,
Switzerland) at 530 nm with background correction at 630 nm. The relative cell viability (%) related to
the buffer-treated control cells was calculated as ([A] test/[A] control) × 100%.
2.11. Cellular Association
Neuro-2a cells were seeded 24 h prior to transfection into 24-well plates at a density of
50,000 cells/well. Culture medium was replaced with 400 µL fresh growth medium 24 h after
seeding the cells. pDNA polyplexes formed at N/P ratio 12 in 100 µL HBG and containing 1 µg
pCMVLuc (20% of Cy5-labeled pCMVLuc) were added to each well and incubated on ice for 30 min.
Subsequently, cells were washed twice with 500 µL PBS. Cells were detached with trypsin/EDTA and
resuspended in PBS with 10% FBS. All experiments were performed in triplicate. Cellular association
of the polyplexes was measured by excitation of Cy5 at 635 nm and detection of emission at 665 nm.
DAPI (4′,6-diamidino-2-phenylindole) staining was used to discriminate between viable and dead
cells. Cells were properly gated by forward/sideward scatter and pulse width for the exclusion of
doublets. Data were recorded by Cyan ADP flow Cytometer (Dako, Hamburg, Germany) using Summit
acquisition software (Summit, Jamesville, NY, USA) and analyzed by FlowJo 7.6.5 flow cytometric
analysis software.
2.12. Cellular Internalization
Neuro-2a cells were seeded 24 h prior to transfection into 24-well plates at a density of
50,000 cells/well. Culture medium was replaced with 400 µL fresh growth medium 24 h after seeding the
cells. pDNA polyplexes formed at N/P ratio 12 in 100 µL HBG and containing 1 µg pCMVLuc (20% of
Cy5-labeled pCMVLuc) were added to each well and incubated at 37 ◦C for 45 min. Subsequently,
cells were washed once with 500 µL PBS containing 1000 IU heparin for 15 min on ice to remove
any polyplexes sticking to the cell surface and again washed once with 500 µL PBS only. Cells were
detached with trypsin/EDTA and resuspended in PBS with 10% FBS. All experiments were performed
in triplicate. Cellular internalization of the polyplexes was measured by the excitation of Cy5 at 635 nm
and detection of emission at 665 nm. DAPI staining was used to discriminate between viable and
dead cells. Cells were properly gated by forward/sideward scatter and pulse width for exclusion
of doublets. Data were recorded by Cyan ADP flow Cytometer (Dako, Hamburg, Germany) using
Summit acquisition software (Summit, Jamesville, NY, USA) and analyzed by FlowJo 7.6.5 flow
cytometric analysis software.
2.13. In Vivo Gene Transfer
Animal experiments were performed in female 6-week-old nude mice, Rj: NMRI-nu (nu/nu)
(Janvier, Le-Genest-St-Isle, France) which were housed in isolated ventilated cages with a 12 h
day/night interval and food and water ad libitum. Huh7 (5 × 106 cells) suspended in 150 µL PBS were
injected subcutaneously into the left flank. After injection, tumor size was monitored with a caliper
and determined by formula a × b2/2 (a = longest side of the tumor; b = widest side vertical to a).
When tumors reached a size of approximately 1200 mm3, the experiments started by intratumoral
injection of 60 µL polyplex solution containing 50 µg pCMVLuc at N/P 12 in HBG. For each polymer,
a group of five mice (n = 5) was treated. Mice were euthanized 48 h later, and tumors were collected to
assess luciferase activity via ex vivo luciferase assay. Tumors were homogenized in 500 µL cell lysis
buffer using a tissue and cell homogenizer (FastPrep®-24). To separate insoluble cell components,
the samples were centrifuged at 3000× g at 4 ◦C for 10 min. Luciferase activity was measured in the
supernatant using a Centro LB 960 luminometer. All animal experiments were performed according to
the guidelines of the German law for the protection of animal life, and were approved by the local
animal ethics committee.
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2.14. Statistical Analysis
Statistical significance was analyzed by Student’s one-tailed t-test. Significance levels are indicated
with symbols: ns p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001.
3. Results and Discussion
3.1. Peptide and Oligomer Synthesis
The objective of this study was to examine different hydrophilic blocks—PAS and PEG—with
varying length in combination with a cationic oligoaminoamide backbone for their “shielding abilities”
in pDNA polyplexes. The cationic oligomers can mainly be divided into two subgroups: a three-arm
cationic topology without shielding domain [58] for control carriers, or shielded two-arm structures
comprising certain PEG or PAS repetitions—topologies are described in Scheme 1. PAS represents
the three neutral amino acids proline, alanine, and serine, ordered from N to C terminus. Solid phase
assisted synthesis (SPS) was used for the assembly of the oligomers listed in Table 1. This method
allowed oligomers to be easily tailored to our needs. The non-shielded positive control with three-arm
topology had a similar number of charge-bearing units (9 Stp, 12 histidines) as the shielded two-arm
oligomers (8 Stp, 11 histidines). A two-arm structure without shielding agent might have been
considered as a suitable control, but previous studies [24] revealed a lower efficacy of short cationic
two-arm oligomers. Moreover, a shielded two-arm in fact presents a three-arm topology (with the
shielding polymer block arm representing the third arm).
The length of shielding blocks used in this study were chosen along the commercially available,
precise PEG derivates of 12 or 24 ethylenoxide (EO) units and analogous PAS peptides. So PAS4
consisting of four PAS repeats (4 × 3 = 12 amino acids) was considered as backbone analog to 12 EO
units (PEG24), and PAS8 (8 × 3 = 24 amino acids) as analog to 24 EO units (PEG24). Due to the amino
acid side groups, the molecular weight of a PAS tri-amino acid block is substantially higher (273 g/mol)
than the analogous EO trimer block (3 × 44 g/mol = 132 g/mol).
Table 1. List of oligomers included in this study. Internal polymer numbers, structures from N to C
terminus, as well as abbreviations used within the paper.
Polymer # Structure Abbreviation
689 [C-(H-Stp)3-H]α,ε-K-H-(Stp-H)3-C 3-arm
1088 {[C-(H-Stp)4-H]α,ε-K-H-dPEG12}ε-K PEG12
1091 {[C-(H-Stp)4-H]α,ε-K-H-dPEG24}ε-K PEG24
1120 {[C-(H-Stp)4-H]α,ε-K-H-dPEG24-dPEG24}ε-K PEG48
1094 {[C-(H-Stp)4-H]α,ε-K-H-(PAS)4}ε-K PAS4
1097 {[C-(H-Stp)4-H]α,ε-K-H-(PAS)8}ε-K PAS8
In case of shielded two-arm structures, first a Dde-L-Lysine-(Fmoc) was loaded on a 2-chlorotrityl
resin. Consequently, the shielding domain was attached to the ε-amine after successful Fmoc
deprotection. It consisted of either monodisperse polyethylene glycol (PEG) of 12, 24, or 2 × 24 units,
or of four or eight repetitive Ser–Ala–Pro units. The cationic backbone consists of histidines, the artificial
amino acid Stp (succinyl-tetraethylene pentamine) [23], lysine, and cysteine. Histidines were introduced
for enhanced endosomal buffering [25,29,59]. Stp was used for nucleic acid packaging, endosomal
buffering, and endosomal escape [58,60]. The diamino acid lysine served as a branching point,
and N-terminal cysteines were introduced for polyplex stabilization via disulfide-crosslinking [24,58,61].
Each oligomer was characterized by 1H-NMR and RP-HPLC. Analytical data can be found in
Figures S7–S30.
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Scheme 1. Schematic structures of the oligomer topologies evaluated in this paper. PAS: proline-
alanine-serine; PEG: polyethylene glycol. 
3.2. Physicochemical Polyplex Characterization 
Oligomer/pDNA interaction was examined in different assays, focusing on pDNA binding 
abilities, stability, and compaction. First, pDNA binding potency of the oligomers was investigated 
by agarose gel electrophoresis shift assays. Here polyplexes were formed with different ratios of 
oligomer to pDNA. This ratio is displayed as N/P, with varying amount of oligomer but constant 
amount of 200 ng pDNA (see Figures S2 and S3). This assay revealed that all tested oligomers 
efficiently complex pDNA at an N/P ratio between 2 and 2.5. We already reported similar findings 
with oligomers composed of the same cationic backbone [25,26]. Importantly, the presence and nature 
of shielding elements did not influence the pDNA binding of the cationic backbone in this assay for 
shielding agents with the length up to PEG24. Only the oligomer with longest PEG48 shielding domain 
exhibited slightly decreased binding potency, since certain fractions of free pDNA could still be 
observed at N/P 3 and 6. Notably, pDNA binding does not necessarily correlate with its degree of 
compaction or polyplex shape. Polyplex properties regarding DNA compaction were therefore 
investigated with alternative techniques (see Section 3.4). 
After pDNA binding was confirmed, particle sizes and zeta potential were determined by 
dynamic light scattering at N/P 12. Results revealed very homogenous particles with a polydispersity 
index (PDI) between 0.04 and 0.33, where 1.0 represents the highest polydispersity (see Table 2). All 
polyplexes show DH values (displayed as Z-Average in nm) in the range between 98 nm and 147 nm. 
It has been reported that particles up to 200 nm can be taken up via a clathrin-dependent pathway 
[62], indicating that subsequent uptake into cells should be possible via endocytosis. DLS data 
provide a hint that particles with shorter shielding agents (PEG12 or PAS4) exhibit smaller particle 
sizes than longer shielding agents. This could be explained by more compact and condensed particles. 
Table 2. Particle size (Z-average), polydispersity index (PDI), and zeta potential of plasmid DNA 
(pDNA) polyplexes formed in HEPES-buffered 5% glucose (HBG) buffer determined with dynamic 
laser-light scattering (DLS). Mean of three measurements of the same sample is indicated. Polymer at 
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Scheme 1. Schematic structures of the oligomer topologies evaluated in this paper. PAS: proline-
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3.2. Physicochemical Polyplex Characterization
Oligomer/pDNA interaction was examined in different assays, focusing on pDNA binding
abilities, stability, and compaction. First, pDNA binding potency of the oligomers was investigated by
agarose gel electrophoresis shift assays. Here polyplexes were formed with different ratios of oligomer
to pDNA. This ratio is displayed as N/P, with varying amount of oligomer but constant amount of
200 ng pDNA (see Figures S2 and S3). This assay revealed that all tested oligomers efficiently complex
pDNA at an N/P ratio between 2 and 2.5. We already reported similar findings with oligomers
composed of the same cationic backbone [25,26]. Importantly, the presence and nature of shielding
elements did not influence the pDNA binding of the cationic backbone in this assay for shielding
agents with the length up to PEG24. Only the oligomer with longest PEG48 shielding domain exhibited
slightly decreased binding potency, since certain fractions of free pDNA could still be observed at
N/P 3 and 6. Notably, pDNA binding does not necessarily correlate with its degree of compaction
or polyplex shape. Polyplex properties regarding DNA compaction were therefore investigated with
alternative techniques (see Section 3.4).
After pDNA binding was confirmed, particle sizes and zeta potential were determined by
dynamic light scattering at N/P 12. Results revealed very homogenous particles with a polydispersity
index (PDI) between 0.04 and 0.33, where 1.0 represents the highest polydispersity (see Table 2).
All polyplexes show DH values (displayed as Z-Average in nm) in the range between 98 nm and
147 nm. It has been reported that particles up to 200 nm can be taken up via a clathrin-dependent
pathway [62], indicating that subsequent uptake into cells should be possible via endocytosis. DLS
data provide a hint that particles with shorter shielding agents (PEG12 or PAS4) exhibit smaller particle
sizes than longer shielding agents. This could be explained by more compact and condensed particles.
Table 2. Particle size (Z-average), polydispersity index (PDI), and zeta pot ntial of plasmid DNA
(pDNA) polyplexes formed in HEPES-buffered 5% glucose (HBG) buffer d termined with dynamic
lase -light scattering (DLS). Mean of three measurements of the same sampl is indicated. Polymer at
nitrogen-to-ph sphate r tio (N/P) 12 and 2 µg plasmi DNA (pDNA) were separately diluted with
HBG pH 7.4 to 30 µL each. Then solutions were mixed and incubated for 30 m n. Polyplexes were
diluted to 800 µL with 10 mM NaCl pH 7.4 prior to me sure ent. Particle size displayed as number
mean can be found in Table S2. # indicates internal library compound IDs.
Polymer # Abbreviation Average size (nm) Average PDI Average zeta potential (mV)
689 3-arm 126.8 ± 2.7 0.15 ± 0.02 32.0 ± 3.5
1088 PEG12 97.9 ± 1.1 0.14 ± 0.02 6.7 ± 2.3
1 91 PEG24 111.6 ± 0.9 16 0.01 3. ± 0.6
1120 PEG48 87.2 ± 1.4 .33 0.05 1.6 ± 0.5
1094 PAS4 127.7 ± 0.8 0.12 0.01 7.1 ± 1.5
1097 PAS8 147.0 ± 1.8 0.15 ± 0.01 3.4 ± 0.8
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3.3. Steric Shielding
As a next step to characterize polyplexes, a stress assay was performed with salt to evaluate the
behavior in isotonic salt concentration. Therefore, PBS buffered at pH 7.4 was added to the polyplexes
after 30 min of incubation in deionized water. DLS measurements were performed immediately after
addition, and at 5, 30, 60, and 180 min. As displayed in Figure 1A, the unshielded three-arm started
to aggregate within 5 min after addition of PBS. Along with the three-arm, PAS4 and PEG12 also
underwent colloidal aggregation. Meanwhile PEG24-, PEG48-, and PAS8-decorated polyplexes showed
colloidal stability over 24 h without any significant aggregation. This indicates that longer PEG or
PAS chains provide improved colloidal stability with lower risk for aggregation, while polyplexes
with shorter PEG length or lack of shielding agent show immediate aggregation after salt addition.
These findings (together with the DNA binding studies) are in accordance with previously published
work where PEG shielding of PEI polyplexes increased the colloidal stability of polyplexes against
salt-induced stress, however at the expense of reduced pDNA binding [63,64].
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Figure 1. (A) Stability testing of untargeted polyplexes against phosphate-buffered saline (PBS).
After 30 min of polyplex incubation (2 µg pDNA; N/P 12) in deionized water and addition of 500 µL
PBS, DLS measurement was performed. Time points 0, 5, 30, 60, and 180 min were displayed. In case
of colloidally-stable polyplexes of PEG24, PEG48, and PAS8, a measurement after 24 h is also displayed.
Data are presented as mean value (±SD) out of triplets; (B) Polyplexes (2 µg pDNA; N/P 12) were
incubated in HBG with or without 3 × 106 erythrocytes. After centrifugation, the supernatant was
taken, and 3500 IU of heparin were added to release pDNA of the polyplexes. Cy5 fluorescence was
compared to uncomplexed (free) pDNA. Statistical analysis (Student’s t-test): ns p > 0.05, * p ≤ 0.05;
** p ≤ 0.01.
The next experiment was designed to investigate the interaction of polyplexes with erythrocytes.
Results are displayed in Figure 1B. Polyplexes in HBG and polyplexes after incubation with
erythrocytes were dissociated by heparin addition, and Cy5 emission of released labeled pDNA
was detected. pDNA can be fully released by heparin (Figure 1B, dark bars) within the range of
experimental accuracy. The data reveal a reduced pDNA recovery due to erythrocyte binding (grey
bars); they also reveal that interaction with erythrocytes decreases with ascending length of the
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shielding agents. PEGylation is known to reduce the interaction of polyplexes with erythrocytes [63],
which is in accordance with our findings.
3.4. DNA Compaction
Transmission electron microscopy (TEM) was performed to investigate polyplex size and shape.
While differences between shielding agents could not be observed by TEM, we observed a clear
difference compared to DH in general, but more unexpected between polyplexes decorated with
shorter or longer shielding agents (Figure 2A). Particles formed out of oligomers with shorter shielding
agents tend to be not only smaller, but also more condensed regarding their structure compared to
polyplexes shielded with longer shielding agents. Polyplexes with PEG12 or PAS4 exhibited sizes of
around 50 nm and a more condensed “rod-like” structure, while PEG24- or PAS8- decorated polyplexes
revealed sizes of approximately 80–100 nm in a “doughnut-like” state. PEG48-decorated polyplexes
revealed the lowest level of compaction and a very erratic shape of around 100 nm in size. Polyplexes
including no shielding agent displayed the most condensed population with sizes around 40–50 nm
in a very compact globular shape. However, polyplexes tend to aggregate due to their charged
surface; this effect is not visible in case of polyplexes decorated with short shielding agents. These
findings are in accordance with recent observations [38], where particle morphology changed from
long rods to globular condensed polyplexes with decreasing amounts of conjugated PEG. To further
investigate the ability to compact pDNA depending on the shielding agent used, pDNA compaction
was determined with an ethidium bromide (EtBr) exclusion assay (Figure 2B). Therefore, 2 µg of pDNA
was mixed with oligomers at either N/P 6 or 12, incubated for 30 min, and then measured after the
addition of EtBr. As reference, linear PEI was included in this study. The intensity of EtBr fluorescence
normalized to uncomplexed pDNA is displayed in Figure 2B (left). These data support the findings
from previous agarose gel shifts and confirm the findings from TEM images. All oligomers complex
pDNA well, but with increased length of shielding agent, pDNA compaction decreased, which can
be seen most pronounced in the case of the longest shielding element PEG48. In the right part of
Figure 2B, fluorescence of the released pDNA of polyplexes is displayed after the addition of 250 IU of
heparin sulfate to cause anionic dissociative stress. Here it can be seen that polyplexes formed with
lPEI and polyplexes decorated with PEG48 completely release pDNA and cause full EtBr fluorescence,
while all other polyplexes are at least partly resistant to the applied heparin stress. Most interestingly,
the shorter the PEG respectively PAS shield, the more resistant the polyplexes were towards heparin
stress. In other words, long PEG (24 or 48 units) or eight PAS repeats tend to destabilize the polyplex.
These results suggest that the cationic charge density of the backbone is just one critical point for
nucleic acid interaction, but the length of the shielding agent also plays a certain role. These findings
from EtBr exclusion assay confirm our results from TEM. They are also in accordance with a most
recent report on lPEI polyplexes [65], where PEGylation caused more sensitivity towards heparin
stress as well as lower compaction in general.
3.5. Serum Stability
Stability of polyplexes in the blood protein environment presents a most relevant and critical issue,
as interaction with proteins can cause aggregation or partial to complete dissociation of the polyplex.
Thus, further experiments were designed to investigate polyplex stability in serum. We applied an
assay to measure polyplex size in 90% FBS with DLS. This method offered the possibility to monitor
polyplex behavior over a long time period from the point of serum addition up to 24 h. Time points
t = 0, 2, 4, 24 h are displayed in Figure 3B–G. Firstly, the size of all polyplexes increased in serum,
from 100–150 nm in 10 mM NaCl to 250–300 nm immediately after addition of FBS. From here on,
a decay (loss of intensity and increase in size) of the polyplexes was observed over time in the case
of the longer shielding agents PEG24 and PAS8, with a tendency towards a higher colloidal stability
of PAS8. PEG12 and PAS4 were the most promising candidates, with almost no decay over time.
While polyplexes shielded with PEG48 underwent immediate decay and aggregation, unshielded
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three-arm underwent no additional changes after the initial size increase within the following 24 h.
An explanation for the elevated stability of three-arm, PAS4, and PEG12 might be the formation of a
serum corona around the polyplexes (which also explains the increased size), and due to the higher
compaction, the ionic complexes remain stable despite serum interaction. Serum corona—especially
when attached to PEGylated nanostructures—has been demonstrated to mediate favorable shielding
properties [66].
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with FBS. In the case of PEGylated polyplexes, a trend towards less pDNA release could be observed 
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Figure 2. (A) Transmission electron microscopy images of polyplexes formed at N/P 12 in deionized
water and stained with uranylformate. Scale bar represents 100 nm; (B) Left: pDNA compaction,
correlating with the remaining fluorescence of ethidium bromide (EtBr). Results are calculated
against free pDNA. Right: Polyplexes at N/P 12 after addition of 250 IU of heparin. lPEI: linear
polyethylenimine. Statistical analysis (Student’s t-test): ns p > 0.05, * p≤ 0.05; ** p≤ 0.01; **** p≤ 0.0001.
In Figure 3H, the behavior of polyplexes after 30 min of incubation with 90% FBS is compared to
polyplexes maintained for the same time in HBG. The amount of released Cy5-labeled pDNA after
addition of heparin was determined. In all cases, pDNA release was lower after polyplex incubation
with FBS. In the case of PEGylated polyplexes, a trend towards less pDNA release could be observed
with increasing PEG length. At least at this early time point, the formation of a serum corona seems
to mediate increased resistance towards polyanionic stress. However, this protective effect seems to
reverse when polyplexes are incubated over a long time in serum, maybe due to the lack of compaction
(see Figure 3C,F,G).
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Figure 3. (A) DLS measurements of 90% fetal bovine serum (FBS, green) and pDNA polyplexes of the
three-arm oligomer in HBG (red) as references to discriminate polyplex and serum peaks; (B–G) Display
behavior of polyplexes with indicated oligomers in 90% FBS over time. In (H), the amount of recovered
pDNA of polyplexes containing Cy5-labeled pDNA after treatment with 3500 IU heparin is displayed
after incubation with FBS for 30 min; HBG-treated polyplexes served as control.
3.6. Tumor Cell Interactions In Vitro
Different interactions of our polyplexes were investigated on N2a (mouse neuroblastoma) cells.
In Figure 4A,B cellular binding is shown. Only polyplexes decorated with PEG48 showed strong
shielding against unspecific binding within 30 min of interaction with cells.
Figure 4C,D displays cellular uptake within 45 min of incubation on cells. Again, only PEG48
polyplexes did not interact with cells and did not mediate significant uptake. In Figure 4E, gene
transfer activity is shown after 0.75 h and 24 h at N/P ratios 6 and 12. After the early 0.75 h time
point, only unshielded three-arm and lPEI polyplexes caused notable gene transfer, while after 24 h
Polymers 2017, 9, 142 13 of 20
of incubation, all polyplexes showed similar transfection efficacy; it is noteworthy that they were as
efficient as lPEI. None of the polyplexes mediated cytotoxicity at any time point (see Figure 4F). These
results suggest that rapid binding and cellular uptake takes place only in case of unshielded cationic
polyplexes (three-arm, lPEI) with sufficient critical endosomal amount of cationic proton sponge
carrier required for efficient endosomal escape and transfection [14,15,67]. In case of oligoaminoamide
carriers with short shielding elements, the internalized amounts of polyplexes increases over time,
reaching sufficient levels for endosomal escape. Only for PEG48 polyplexes, notable transfection is
not even reached after 24 h. Either the critical amount for endosomal escape is not reached, or the
longer PEG domain hampers the endosomal membrane disruption. The widely known effect that
introduction of PEG into cationic transfection complexes can reduce transfection efficacy has been
referred to as the “PEG dilemma” [56]. For PEI-type polyplexes, it has been assumed that a combined
effect of osmotic endosomal burst and direct phospholipid destabilization by the cationized carrier
is required for endosomal escape [6,18,68,69]; obviously, PEGylation can hinder the direct cationic
membrane destabilization. Consistently, bioreversible PEGyation was demonstrated to resolve this
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For this study, a phage-derived peptide (cmb) binding specifically to the HGF (hepatocyte 
growth factor)-receptor cMet [71,72] was introduced into our oligomers via modification at the α-
amine of the c-terminal lysine. A complete list of cmb-containing oligomers can be found in Table S1. 
cMet is widely overexpressed in epithelial-derived tumors as well as stromal and interstitial cell-
derived tumors (e.g., sarcomas) [73], and was pointed out previously as a suitable target for tumor 
Figure 4. In (A,B) cellular association of polyplexes with N2a cells after 30 min incubation at 4 ◦C as
determined by flow cytometry is plotted; In (C,D) cellular internalization of polyplexes after 45 min
incubation at 37 ◦C followed by removal of extracellularly-bound polyplexes is displayed; Logarithmic
X-scale in (A–D) represents Cy5 fluorescence of polyplexes; (E) Luciferase reporter gene expression in
N2a cells after 0.75 h (without pattern) and after 24 h (with pattern). Transfections were performed
at two different ratios: N/P = 6 (red) and N/P = 12 (green). (F) Cell viability assay was performed
in parallel.
3.7. Tumor Cell Interactions In Vitro without and with Targeting
For this study, a phage-derived peptide (cmb) binding specifically o the HGF (hepatocyte growth
factor)-receptor cMet [71,72] was introduced into our oligomers via modification at th α-amine of the
c-terminal lysine. A complete list of cmb-contai ing oligomers can be found in Table S1. cMet is widely
overexpressed in epithelial-derived tumors as well as stromal and interstitial cell-derived tumors (e.g.,
sarcomas) [73], and was pointed out previously as a suitable target for tumor targeting [72,74,75];
introduction of cmb into sequence-defined oligomers improved transfection efficacy over untargeted
controls in vitro as well as in vivo [25,74].
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In the current work, transfections of two cMet–overexpressing cell lines—the DU145 prostate
cancer cell line (Figure 5A) and the Huh7 hepatocellular cancer cell line (Figure 5B)—were carried
out with polyplexes without or with cMet targeted ligands. With both cell lines, results were
consistent with the previous N2a transfections; short-term incubations with polyplexes for 45 min
only mediated moderate gene transfer, while higher gene expression was observed after a longer
transfection time of 24 h. Transfection of Huh7 with cmb-PAS8 (no increase with time) presents an
exemption from this rule. In case of the PEG12 containing polymer, we observed an elevating effect
of the introduction of the cmb targeting peptide on transfection efficacy. Further on, transfection
efficacy of PEG12 decorated polyplexes tended to be higher than with PEG24-decorated polyplexes.
This increased transfection efficacy could be affiliated with the beneficial compact, rod-like structure of
PEG12-containing polyplexes [76]. MTT assays for both cell lines were also performed in parallel to
transfections, and did not show notable cytotoxicity at any time point (see Figure S4). In addition to the
transfections of cMet-positive cell lines, transfections of receptor negative N2a cells (for 0.75 h and 24 h)
with targeted polyplexes can be found in Figure 5SA. No significant gene transfer was observed after
0.75 h. After 24 h, polyplexes had been taken up unspecifically and caused notable gene transfer in the
case of cmb-3-arm, cmb-PEG12, and cmb-PEG24. cmb-PAS4 and cmb-PAS8 hardly mediated any gene
transfer. Cytotoxicity was not observed (Figure 5SB).
3.8. Tumor Cell Interactions In Vivo without and with Targeting
An in vivo experiment was the next logical step to further evaluate the potency of our oligomers.
As a first step, intratumoral application into a subcutaneous Huh7 mouse model was chosen.
Kos et al. [25] pointed out in the same model that polyplexes formed with cmb-PEG24 were superior
to cmb-PEG48 in gene transfer. Therefore, in the current experiments, untargeted as well as targeted
polyplexes of 3-arm, PEG12, and PAS4 were intratumorally injected into mice.
Untargeted, unshielded 3-arm mediated the highest gene transfer, as already observed in vitro
(see Figures 4E and 5A,B). This might be explained by the local stickiness of unshielded surface and
in the tumor. At the same time, polyplexes with PEG12 mediated decreased transgene expression,
indicating a successful shielding in vivo. By introduction of targeting peptide cmb into PEG12-shielded
polyplexes, transfection efficacy was recovered again. Overall, luciferase gene expression was also
increased as compared to cmb-PEG24 [25], which extends the already previously observed trend of
increasing gene transfer activity with decreasing PEG length (PEG48 < PEG24 < PEG12). Interestingly,
recent work with lPEI polyplexes [65] also reported favorable properties for incorporating targeting
peptides via a 500–700 Da PEG molecule, which has similar size as PEG12.
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be synthesized by SPS and used for the formation of shielded pDNA. Within the performed in vitro 
structure–activity relationship studies, polyplexes shielded with PEG and PAS of comparable length 
exhibited similar properties. This finding remains to be extended by in vivo pharmacokinetic 
experiments investigating systemic circulation and biodistribution. Independent of the hydrophilic 
block, the length had clear opposite effects on shielding and compaction of formed pDNA 
nanoparticles. In sum, it is notable that opposing requirements have to be dealt with balanced 
measures; both extremes (no shielding or very long shielding) have their drawbacks. The oligomer 
characteristics are summarized in Table 3. In the current study with two-arm oligoaminoamide 
pDNA polyplexes, the shorter PEG12 domain is considered to be the best compromise. Similar 
conclusions have been recently reported by other researchers both for shielded lPEI polyplexes [65] 
and liposomes [77]. These findings were also confirmed for polymers containing the targeting 
peptide cmb. The cmb-PEG12 shielded polyplexes showed the most pronounced effect of cMet 
targeting and mediated the most potent gene transfer in vitro as well as in vivo. 
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PBS resistance: +/– indicates Yes/No; Erythrocyte adhesion: +++ lowest adhesion, ++ low adhesion, + increased 
adhesion, – complete adhesion; Particle compaction: +++ highest compaction, ++ mediate compaction, + 
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against 250 IU: +/– indicates Yes/No; Serum stability: +/– indicates Yes/No; Shielding: +++ zeta potential (ZP) < 2 
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to untreated cells. 
Figure 5. (A) Luciferase reporter gene expression in human prostate cancer cell line DU145 as well
as in (B) human hepatocellular cancer cells Huh7 after 0.75 h (without pattern), and after 24 h (with
pattern). Transfections were performed at two different ratios: N/P = 6 (red) and N/P = 12 (green);
(C) Luciferase gene expression at 48 h after intratumoral administration of pCMVLuc polyplexes at
N/P = 12 into Huh7 tumor-bearing mice. Luciferase gene expression is presented as relative light units
per gram tumor (RLU/g tumor; n = 5, mean ± SEM). Lysis buffer RLU values were subtracted.
4. Conclusions
Fo this study, we synthesize pDNA p ly lexes d corated with highly defined PEG as well
as PAS repetitions fo surface shielding. We compared them side-by-side and with an unshielded
control oligomer. Firstly, PAS4- and PAS8-decorated sequence-defined oligo(ethanamino)amides
can be synthesized by SPS and sed for the formation of shielded pDN . Within the performed
in vitro structure–activity relationship studies, polyplexes shielded with PEG and PAS of comparable
length exhibited similar properties. This finding remains to be extended by in vivo pharmacokinetic
experiments investigating systemic circulation and biodistribution. Independent of the hydrophilic
block, the length had clear opposite effects on shielding and compaction of formed pDNA nanoparticles.
In sum, it is notable that opposing requirements have to be dealt with balanced measures; both
extremes (no shielding or very long shielding) have their drawbacks. The oligomer characteristics
are summarized in Table 3. In the current study with two-arm oligoaminoamide pDNA polyplexes,
the shorter PEG12 domain is considered to be the best compromise. Similar conclusions have been
recently reported by other researchers both for shielded lPEI polyplexes [65] and liposomes [77]. These
findings were also confirmed for polymers containing the targeting peptide cmb. The cmb-PEG12
shielded polyplexes showed the most pronounced effect of cMet targeting and mediated the most
potent gene transfer in vitro as well as in vivo.
Table 3. Summary of oligomer characteristics.
Experiment Oligomers
3-arm PEG12 PEG24 PEG48 PAS4 PAS8
PBS resistance – – + + – +
Erythrocyte adhesion – ++ ++ +++ + +
Particle compaction +++ ++ + – ++ +
Polyplex shape globule rod-like doughnut aggregates cord-like rod-like doughnut
Heparin resistance + + – – + +
Serum stability + + – – + –
Shielding – + + + + + ++
Tr nsf ction (sh rt term) + – – – – –
Transfection (long term) + + + v + +
PBS resistance: +/– indicates Yes/ o; Erythrocyte adhesion: +++ lowest adhesion, ++ low adhesion, + increased
adhesion, – complete adhesion; Particle compaction: +++ highest compaction, ++ mediate compaction, + compaction,
– no sufficient compaction (evaluated by EtBr exclusion assay and TEM images); Heparin resistance against 250 IU:
+/– indicates Yes/No; Serum stability: +/– indicates Yes/No; Shielding: +++ zeta potential (ZP) < 2 mV, ++ ZP < 5 mV,
+ ZP < 10 mV, – ZP > 10 mV; Transfection efficacy of polyplexes on N2a cells (short as well as long-term): + significant
transfection efficacy compared to untransfected cells, – no transfection signal compared to untreated cells.
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